

SCIENTIFIC PROGRAM

Registration

Secretariat personnel will be present from 4:00 p.m. on Wednesday, July 9, 2003, on the 6th floor foyer of the New York Marriott Marquis for registration and assistance to the participants.

Scientific Session Schedule

The scientific sessions will be scheduled as follows:

Thursday, July 10, 2003	8:30 a.m. – 6:30 p.m.
Friday, July 11, 2003	8:30 a.m. – 7:30 p.m.
Saturday, July 12, 2003	8:30 a.m. – 6:30 p.m.
Sunday, July 13, 2003	8:30 a.m. – 11:00 a.m.

Thursday, July 10, 2003

Morning: 8:30 – 10:35 a.m.

Opening Remarks

The Evolution of Triglycerides as a Coronary Risk Factor
A.M. Gotto, Jr. (New York, NY)

PLENARY SESSION

EPIDEMIOLOGY

EPIDEMIOLOGY OF HYPERTRIGLYCERIDEMIA AND REMNANTS IN CVD

E.J. Schaefer (Boston, MA, USA)

DYSLIPIDEMIA, INSULIN RESISTANCE, AND TYPE 2 DIABETES

M.-R. Taskinen (Helsinki, Finland)

HETEROGENEITY OF THE LOW HDL SYNDROME

G. Assmann (Munster, Germany)

OVERWEIGHT AND OBESITY

B.V. Howard (Washington, D.C., USA)

Friday, July 11, 2003

Morning: 8:30 – 10:35 a.m.

PLENARY SESSION

MECHANISMS: FREE FATTY ACIDS, TRIGLYCERIDES, AND LIPOPROTEIN METABOLISM

REGULATION OF TRIGLYCERIDE METABOLISM IN ADIPOSE TISSUE AND LIVER

R. Eckel (Denver, CO, USA)

TRIGLYCERIDE METABOLISM IN SKELETAL MUSCLE: LINKS TO INSULIN RESISTANCE

D. Stein (The Bronx, NY, USA)

FABS AND FAT: FATTY ACID BINDING PROTEINS AND TRANSPORT PROTEINS

M. Linton (Nashville, TN, USA)

MECHANISMS OF HEPATIC VLDL OVERPRODUCTION

H. Ginsberg (New York, NY, USA)

NEW INSIGHTS INTO TRIGLYCERIDE AND LIPOPROTEIN METABOLISM: ROLE OF ABC TRANSPORTERS

H.B. Brewer, Jr. (Bethesda, MD, USA)

Saturday, July 12, 2003

Morning: 8:30 – 10:35 a.m.

PLENARY SESSION

INTERVENTION, PREVENTION, AND TREATMENT

ADDRESSING THE DIABETES EPIDEMIC: TREATMENT AND PREVENTION

D.M. Nathan (Boston, MA, USA)

CARDIOPROTECTIVE EFFECTS OF OMEGA 3 FATTY ACIDS

W.S. Harris (Kansas City, MO, USA)

STATINS IN DIABETES MELLITUS/METABOLIC SYNDROME

E. Stein (Highland Heights, KY, USA)

FIBRATES, PPAR α , AND ATHEROSCLEROSIS IN DIABETES MELLITUS AND THE METABOLIC SYNDROME

J.-C. Fruchart (Lille, France)

THE USE OF PPAR γ AGONISTS FOR THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES MELLITUS

E. Horton (Burlington, VT, USA)

Sunday, July 13, 2003

Morning: 8:30 – 11:00 a.m.

PLENARY SESSION (DEBATE)

THE METABOLIC SYNDROME

- DIFFERING PERSPECTIVES ON THE METABOLIC SYNDROME
- THERAPEUTIC OPTIONS
- TREATMENT AND APPROVABLE INDICATIONS BY REGULATORY AGENCIES

The Scientific Program will also include:

A) Symposia

Intervening in the Cardiovascular Risk Continuum: New Areas for Focus

*Supported in part by an unrestricted educational grant from
AstraZeneca Pharmaceuticals*

Atherosclerosis, Inflammation, and the Metabolic Syndrome: Putting the Pieces Together

*Supported in part by an unrestricted educational grant from
Bristol-Myers Squibb Company*

The Patient With the Metabolic Syndrome: Challenges and Opportunities in Risk Reduction

*Supported in part by an unrestricted educational grant from
Fournier Pharma*

The Role of Tight Control of Diabetes versus Lipid Modification in Cardiovascular Risk Reduction

*Supported in part by an unrestricted educational grant from
Kos Pharmaceuticals, Inc.*

The Metabolic Syndrome: More Than Its Components?

*Supported in part by an unrestricted educational grant from
Merck & Co., Inc.*

Evolving Role of Combination Therapy in the Management of Dyslipidemia

*Supported in part by an unrestricted educational grant from
Merck/Schering-Plough Pharmaceuticals*

Clinical Benefits of Aggressive Lipid Therapy in Patients with High Global Risk

*Supported in part by an unrestricted educational grant from
Pfizer Inc.*

B) Workshops of Invited Lectures and Selected Oral Communications.

The Program Committee will choose the best submitted abstracts to be included as Oral Communications in the Workshops.

1. ADIPOSE TISSUE
J.P. Després (Toronto, Canada), **P. Grimaldi** (Nice, France)
2. CASE STUDIES
Cornell Faculty
3. DRUG TREATMENT TO REDUCE CVD RISK IN METABOLIC SYNDROME
T.A. Pearson (Rochester, NY, USA), **G. Steiner** (Toronto, Canada)
4. EPIDEMIOLOGY OF HYPERTRIGLYCERIDEMIA IN POPULATION GROUPS (AGE, GENDER, ETHNICITY)
F.K. Welty (Boston, MA, USA), **M.A. Austin** (Seattle, WA, USA)
5. FATTY ACID METABOLISM
H. Chen (San Francisco, CA, USA), **M. Jensen*** (ROCHESTER, MN, USA),
G. Vega (DALLAS, TX, USA) **invited, not confirmed*
6. LIPOPROTEIN, HEPATIC AND ENDOTHELIAL LIPASES
I. Goldberg (New York, NY, USA), **D. Rader** (Philadelphia, PA, USA)
7. METABOLIC SYNDROME AND DIABETES: PATHOPHYSIOLOGY AND MECHANISMS
P.D. Reaven (Phoenix, AZ, USA), **J. Plutzky** (Boston, MA, USA)
8. NONPHARMACOLOGICAL INTERVENTION
M. Katan (Amsterdam, The Netherlands), **N. Cater** (Dallas, TX, USA), **P. Thompson** (Hartford, CT, USA)
9. POSTPRANDIAL LIPEMIA
A. Catapano (Milan, Italy)
10. REGULATORY PROTEINS
P.J.H. Jones (Quebec, Canada), **C. Steppan** (Philadelphia, PA, USA)
11. SYNTHESIS AND METABOLISM OF TRIGLYCERIDE-RICH LIPOPROTEINS
E.J. Schaefer (Boston, MA, USA), **H. Ginsberg** (New York, NY, USA)
12. TRIGLYCERIDE-RICH LIPOPROTEINS, INFLAMMATION, AND ATHEROSCLEROSIS
P. Barter (Sydney, Australia), **C. Ballantyne** (Houston, TX, USA)

C) Selected Oral Communications (See page 8)

D) Posters (See page 8)

Friday, July 11, 2003 6:00 p.m. - 7:30 p.m.

Poster Session and Reception

All registered participants are welcome to view the posters and discuss with the authors the highlights of the session. Drinks and light refreshments will be offered.

*Funding for the Poster Session Reception is graciously provided by
Sankyo Pharma Inc.*

E) Case Studies